Why this conversation matters
Some people see a substantial rise in LDL cholesterol while following a ketogenic diet. In this interview, Toward Health clinicians and lipid researcher Dr. Joshua “Josh” Wageman discuss research on ezetimibe and the questions it raises about individual cholesterol responses.
For someone who feels better on a ketogenic diet, a sharp rise in LDL can create a difficult question. What does the change mean, and can it be addressed without giving up an approach that feels helpful? This conversation explores one possible treatment response while being clear about what a small, selected case series cannot tell us about other patients or long-term heart health.
Meet the participants
Dr. Tro Kalayjian, DO, is Toward Health’s founder and Chief Medical Officer, board-certified in Internal Medicine and Obesity Medicine. Dr. Laura Buchanan, MD, serves as Executive Director of Physicians and Research. She is board-certified in Family Medicine and Obesity Medicine, with a focus on prevention and metabolic health.
Dr. Matthew “Matt” Calkins, MD, is Toward Health’s Medical Director, board-certified in Family Medicine and Obesity Medicine, with clinical and research interests in metabolic health. Dr. Joshua Wageman is a lipid researcher and coauthor of the ezetimibe study. Together, they bring clinical and research perspectives to a question that matters to patients whose LDL rises on keto.
What the study found
The retrospective case series selected 14 ketogenic-diet patients with marked LDL responses to ezetimibe. Median LDL cholesterol was 254 mg/dL before treatment and 127 mg/dL afterward; the median within-person reduction was 53.2%. Twelve patients received ezetimibe alone, and two also took a statin. The paper was published in Lipids in Health and Disease.
These results describe selected strong responders, not the expected response for everyone on keto. The small study had no control group. It cannot prove the proposed cholesterol-absorption mechanism or show that treatment prevented heart attacks. Medication decisions require individual clinical assessment; this article is not a recommendation to start or stop treatment.
For more background, explore Toward Health’s companion research explainer.
